Fleming, D R <br/><br/>
Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group.  [electronic resource] 

 -  Leukemia & lymphoma  Sep 1999 
 - 91-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1042-8194 
<br/><br/><label>Standard No.: </label>10.3109/10428199909145708  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carmustine--administration & dosage<br/>Combined Modality Therapy<br/>Cyclophosphamide--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Etoposide--administration & dosage<br/>Hematopoietic Stem Cell Transplantation<br/>Hodgkin Disease--therapy<br/>Humans<br/>Infusions, Intravenous<br/>Middle Aged<br/>North America<br/>Recurrence<br/>Transplantation, Autologous<br/>Treatment Outcome